clinical trial · NCT07002398
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1VG801
brief summary
This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for treatment of patients with retinal dystrophy (Stargardt disease) due to biallelic ABCA4 mutations.
started
Dec 23, 2024
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Dec 11, 2025
official title
A Single Arm, Ph1/2, Open-label, Multicenter Trial With Dose-exploration Via Subretinal Injection to Evaluate the Safety and Preliminary Efficacy of VG801 for Treatment of ABCA4 Mutation-associated Recessive Hereditary Retinal Dystrophy (Stargardt Disease)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol